Cilostazol: a review of its use in intermittent claudication.

[1]  J. Cardella,et al.  Position statement on the use of the ankle brachial index in the evaluation of patients with peripheral vascular disease. A consensus statement developed by the Standards Division of the Society of Interventional Radiology. , 2002, Journal of vascular and interventional radiology : JVIR.

[2]  P. Thompson,et al.  Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication , 2002 .

[3]  J. Crouse,et al.  Clinical Manifestation of Atherosclerotic Peripheral Arterial Disease and the Role of Cilostazol in Treatment of Intermittent Claudication , 2002, Journal of clinical pharmacology.

[4]  J. Ware,et al.  Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials , 2002, Journal of the American Geriatrics Society.

[5]  J. Olin,et al.  MANAGEMENT OF PATIENTS WITH INTERMITTENT CLAUDICATION , 2002, International journal of clinical practice.

[6]  Yongge Liu,et al.  New Mechanism of Action for Cilostazol: Interplay Between Adenosine and Cilostazol in Inhibiting Platelet Activation , 2002, Journal of cardiovascular pharmacology.

[7]  B. Fernandez.  A rational approach to diagnosis and treatment of intermittent claudication. , 2002, The American journal of the medical sciences.

[8]  K. Kwon,et al.  Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans , 2002, Clinical pharmacology and therapeutics.

[9]  D. Strandness,et al.  Effect of Cilostazol in Patients with Intermittent Claudication: A Randomized, Double-Blind, Placebo-Controlled Study , 2002, Vascular and endovascular surgery.

[10]  M. Rendell,et al.  Cilostazol Treatment of Claudication in Diabetic Patients , 2002, Current medical research and opinion.

[11]  R. Villareal,et al.  Rapid ventricular tachycardias associated with cilostazol use. , 2002, Texas Heart Institute journal.

[12]  Yongge Liu,et al.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. , 2006, Cardiovascular drug reviews.

[13]  Yongge Liu,et al.  Interplay Between Inhibition of Adenosine Uptake and Phosphodiesterase Type 3 on Cardiac Function by Cilostazol, an Agent to Treat Intermittent Claudication , 2001, Journal of cardiovascular pharmacology.

[14]  Y. T. Lee,et al.  Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. , 2001, Atherosclerosis.

[15]  W. Mcghan.  PCV7: COST-UTILITY ANALYSIS OF DRUG THERAPY OPTIONS FOR INTERMITTENT CLAUDICATION , 2001 .

[16]  Y. Nakaya,et al.  Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. , 2001, Life sciences.

[17]  E. Mohler,et al.  Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication , 2001, Vascular medicine.

[18]  M. Aoki,et al.  Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model , 2001, Diabetologia.

[19]  D. Dawson,et al.  Comparative effects of cilostazol and other therapies for intermittent claudication. , 2001, American Journal of Cardiology.

[20]  C. Pratt.  Analysis of the cilostazol safety database. , 2001, The American journal of cardiology.

[21]  K. Nakamura,et al.  Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. , 2001, Thrombosis research.

[22]  M. Reilly,et al.  Cilostazol: Treatment of Intermittent Claudication , 2001, The Annals of pharmacotherapy.

[23]  K. Tanemoto,et al.  Assessment of antithrombotic agents using the platelet aggregation test , 2000 .

[24]  D. Dawson,et al.  A comparison of cilostazol and pentoxifylline for treating intermittent claudication. , 2000, The American journal of medicine.

[25]  Sheng Wang,et al.  Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. , 2000, Journal of cardiovascular pharmacology.

[26]  M. Odomi,et al.  In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms , 2000, Human & experimental toxicology.

[27]  Y. Taniyama,et al.  Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. , 2000, Hypertension.

[28]  A. Munakata,et al.  Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus , 2000, Pathophysiology of Haemostasis and Thrombosis.

[29]  Y. Kimura,et al.  Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. , 1999, Thrombosis research.

[30]  D. Dawson,et al.  A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. , 1999, Archives of internal medicine.

[31]  K. Bornfeldt,et al.  Cyclic Nucleotide Phosphodiesterases and Human Arterial Smooth Muscle Cell Proliferation , 1999, Thrombosis and Haemostasis.

[32]  D. Dawson,et al.  The effect of withdrawal of drugs treating intermittent claudication. , 1999, American journal of surgery.

[33]  M. Prins,et al.  Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. , 1999, Archives of internal medicine.

[34]  W. Forbes,et al.  Interaction Potential and Tolerability of the Coadministration of Cilostazol and Aspirin , 1999, Clinical pharmacokinetics.

[35]  A. Suri,et al.  Inhibition of CYP2D6 by Quinidine and its Effects on the Metabolism of Cilostazol , 1999, Clinical pharmacokinetics.

[36]  W. Forbes,et al.  Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics , 1999, Clinical pharmacokinetics.

[37]  W. Forbes,et al.  Effect of Renal Impairment on the Pharmacokinetics of Cilostazol and its Metabolites , 1999, Clinical pharmacokinetics.

[38]  W. Forbes,et al.  Effects of CYP3A Inhibition on the Metabolism of Cilostazol , 1999, Clinical pharmacokinetics.

[39]  W. Forbes,et al.  Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol , 1999, Clinical pharmacokinetics.

[40]  A. Corey,et al.  Effect of Multiple Cilostazol Doses on Single Dose Lovastatin Pharmacokinetics in Healthy Volunteers , 1999, Clinical pharmacokinetics.

[41]  S. Mallikaarjun,et al.  Effect of Cilostazol on the Pharmacokinetics and Pharmacodynamics of Warfarin , 1999, Clinical pharmacokinetics.

[42]  W. Forbes,et al.  Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease , 1999, Clinical pharmacokinetics.

[43]  A. Suri,et al.  Effect of Omeprazole on the Metabolism of Cilostazol , 1999, Clinical pharmacokinetics.

[44]  J. Crouse,et al.  Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[45]  D. Dawson,et al.  Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. , 1998, Circulation.

[46]  T. Itoh,et al.  Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine‐induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit , 1998, British journal of pharmacology.

[47]  J. A. Herd,et al.  Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. , 1998, Journal of vascular surgery.

[48]  Yasuo Ikeda,et al.  Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. , 1997, Life sciences.

[49]  A. Kashiwagi,et al.  Cilostazol, a cAMP Phosphodiesterase Inhibitor, Attenuates the Production of Monocyte Chemoattractant protein-1 in Response to Tumor Necrosis Factor-α in Vascular Endothelial Cells , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[50]  D L Sackett,et al.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. , 1996, Circulation.

[51]  U. Ikeda,et al.  Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. , 1996, European journal of pharmacology.

[52]  D. Moher,et al.  Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. , 1996, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[53]  Y. Okuda,et al.  Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. , 1996, Biochemical and molecular medicine.

[54]  L. B. Barradell,et al.  Oral Naftidrofuryl , 1996, Drugs & aging.

[55]  J. Regensteiner,et al.  Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. , 1995, Circulation.

[56]  E. Ernst.  Pentoxifylline for Intermittent Claudication , 1994, Angiology.

[57]  Sadao Takahashi,et al.  Effect of Cilostazol, a Cyclic AMP Phosphodiesterase Inhibitor, on the Proliferation of Rat Aortic Smooth Muscle Cells in Culture , 1992, Journal of cardiovascular pharmacology.

[58]  T. Tani,et al.  Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. , 1990, Thrombosis research.

[59]  M. Hagiwara,et al.  Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. , 1988, Pharmacology.

[60]  E. Barrett-Connor,et al.  TABLE 1 Prevalence of PAD by traditional assessment : intermittent claudication and pulse palpation % Claudication % Pulse abnormalities Rose Femoral Posterior Dorsalis n Rose , 2005 .

[61]  K. Yasuda,et al.  Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. , 1985, Arzneimittel-Forschung.

[62]  Y. Morioka,et al.  Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. , 1985, Arzneimittel-Forschung.

[63]  T. Niki,et al.  Phase I study of cilostazol. Safety evaluation at increasing single doses in healthy volunteers. , 1985, Arzneimittel-Forschung.

[64]  H. Akiyama,et al.  The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. , 1985, Arzneimittel-Forschung.

[65]  K. Yasunaga,et al.  Clinical effects of oral cilostazol on suppression of platelet function in patients with cerebrovascular disease. , 1985, Arzneimittel-Forschung.

[66]  K. Yasunaga,et al.  Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. , 1985, Arzneimittel-Forschung.

[67]  H. Akiyama,et al.  The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man. , 1985, Arzneimittel-Forschung.

[68]  H. Sasabe,et al.  General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs. , 1985, Arzneimittel-Forschung.

[69]  Y. Kimura,et al.  Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. , 1985, Arzneimittel-Forschung.

[70]  T. Tani,et al.  Effect of cilostazol on platelet aggregation and experimental thrombosis. , 1985, Arzneimittel-Forschung.